abstract |
There is provided a complex comprising rifaximin and a complexing agent, wherein the ncomplexing agent is a polyvinyl pyrrolidone (PVP) or a cyclodextrin. There is also n5 provided a process for preparing the complex, a pharmaceutical composition including nthe complex and therapeutic uses of the complex. n11765256_1 (GHMatters) P87152.AU.3 |